Review

Molecular mechanisms of castration-resistant prostate cancer progression

University of California School of Medicine at Davis, CA, USA

† Author for correspondence

Department of Urology and Cancer Center, Research III Bldg, Suite 1300, University of California School of Medicine at Davis, 4645 2nd Ave, Sacramento, CA 95817, USA.

Search for more papers by this author

Email the corresponding author at acgao@ucdavis.edu

Published Online:10 Nov 2009https://doi.org/10.2217/fon.09.117

View article

Abstract

Hormone-refractory prostate cancer is the result of regrowth of prostate cancer cells that have adapted to the hormone-deprived environment of the prostate. The process by which castration-resistant prostate cancer (CRPC) cells are generated appears to be varied. The complex mechanism of hormone resistance has been the topic of research in most laboratories that have analyzed the process from different angles. This review compiles research findings that explain the methods of development of hormone resistance in prostate cancer. Research data show many different processes to be involved in the acquisition of hormone resistance. Interestingly, one observes interdependence between these processes, indicating a complex network at play in the development of hormone resistance. Cytokines such as IL-6 have been shown to initiate an alternative signaling pathway, compared with the androgen receptor signaling pathway, in CRPC. IL-6 has been proposed to be the effector of the intracrine signaling pathway by influencing the levels of metabolic enzymes. Neuroendocrine cells are present at low levels in normal prostate, and signify the transitory phase of normal hormone-sensitive cells to hormone-refractory cells. IL-6 induces growth of neuroendocrine cells or neuroendocrine-like features in cells in CRPC. The increased presence of neuroendocrine cells in CRPC signifies a change in the prostate cell microenvironment. The stromal microenvironment also influences the development of CRPC in the hormone-refractory stage. In addition, intracrine androgen metabolic enzymes play a significant role in the development of the hormone refractory process. Despite hormone ablation, there is a residual level of hormones in cells due to active intracrine metabolic pathways. It is acknowledged that the androgen receptor plays the most influential role in development of prostate cancer. In addition to mutation and amplification, the androgen receptor has been characterized and shown to differ in sequence in CRPC compared with the androgen-sensitive prostate cancer cells. These variants of the androgen receptor through sequence changes may preserve the basic function of the molecule, but have far-reaching consequences on the cell as a whole. A multicombinatorial drug treatment approach has been suggested to target these multiple pathways in an effort to reduce the possibility of recurrence of CRPC.

Keywords:

Bibliography

1 Isaacs JT: Role of androgens in prostatic cancer. Vitam. Horm.49,433–502 (1994).Crossref, Medline, CAS, Google Scholar
2 Trapman J, Cleutjens KB: Androgen-regulated gene expression in prostate cancer. Semin. Cancer Biol.8(1),29–36 (1997).Crossref, Medline, CAS, Google Scholar
3 Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin.22(4),232–240 (1972).Crossref, Medline, CAS, Google Scholar
4 Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res.55(14),3068–3072 (1995).Medline, CAS, Google Scholar
5 van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al.: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer48(2),189–193 (1991).Crossref, Medline, CAS, Google Scholar
6 Huggins CMD, Hodges CV: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.19,293–297 (1941).Google Scholar
7 Dehm SM, Tindall DJ: Regulation of androgen receptor signaling in prostate cancer. Expert Rev. Anticancer Ther.5(1),63–74 (2005).Crossref, Medline, CAS, Google Scholar
8 Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat. Rev. Cancer1(1),34–45 (2001).Crossref, Medline, CAS, Google Scholar
9 Pienta KJ, Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res.12(6),1665–1671 (2006).Crossref, Medline, CAS, Google Scholar
10 Arnold JT, Isaacs JT: Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell’s fault. Endocr. Relat. Cancer9(1),61–73 (2002).Crossref, Medline, CAS, Google Scholar
11 Lee SO, Lou W, Hou M, Onate SA, Gao AC: Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene22(39),7981–7988 (2003).Crossref, Medline, Google Scholar
12 Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res.9(1),370–376 (2003).Medline, CAS, Google Scholar
13 Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl Cancer Inst.93(22),1687–1697 (2001).Crossref, Medline, CAS, Google Scholar
14 Shi XB, Ma AH, Tepper CG et al.: Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate60(3),257–271 (2004).Crossref, Medline, CAS, Google Scholar
15 Chen Q, Watson JT, Marengo SR et al.: Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett.244(2),274–288 (2006).Crossref, Medline, CAS, Google Scholar
16 Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv. Immunol.54,1–78 (1993).Crossref, Medline, CAS, Google Scholar
17 Murakami M, Hibi M, Nakagawa N et al.: IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science260(5115),1808–1810 (1993).Crossref, Medline, CAS, Google Scholar
18 Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD: Interleukin-6: structure-function relationships. Protein Sci.6(5),929–955 (1997).Crossref, Medline, CAS, Google Scholar
19 Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I: Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res.50(24),7786–7788 (1990).Medline, CAS, Google Scholar
20 Siegsmund MJ, Yamazaki H, Pastan I: Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J. Urol.151(5),1396–1399 (1994).Crossref, Medline, CAS, Google Scholar
21 Hobisch A, Rogatsch H, Hittmair A et al.: Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol.191(3),239–244 (2000).Crossref, Medline, CAS, Google Scholar
22 Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate41(2),127–133 (1999).Crossref, Medline, CAS, Google Scholar
23 Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol.161(1),182–187 (1999).Crossref, Medline, CAS, Google Scholar
24 Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res.57(1),141–146 (1997).Medline, CAS, Google Scholar
25 Hobisch A, Eder IE, Putz T et al.: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res.58(20),4640–4645 (1998).Medline, CAS, Google Scholar
26 Chen T, Wang LH, Farrar WL: Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res.60(8),2132–2135 (2000).Medline, CAS, Google Scholar
27 Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate42(3),239–242 (2000).Crossref, Medline, CAS, Google Scholar
28 Lee SO, Lou W, Johnson CS, Trump DL, Gao AC: Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate60(3),178–186 (2004).Crossref, Medline, CAS, Google Scholar
29 Inoue K, Slaton JW, Eve BY et al.: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res.6(5),2104–2119 (2000).Medline, CAS, Google Scholar
30 Araki S, Omori Y, Lyn D et al.: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res.67(14),6854–6862 (2007).Crossref, Medline, CAS, Google Scholar
31 Yang HP, Woodson K, Taylor PR et al.: Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur. J. Cancer Prev.15(3),249–253 (2006).Crossref, Medline, CAS, Google Scholar
32 Lee LF, Louie MC, Desai SJ et al.: Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene23(12),2197–2205 (2004).Crossref, Medline, CAS, Google Scholar
33 Gujral A, Burton DW, Terkeltaub R, Deftos LJ: Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence. Cancer Res.61(5),2282–2288 (2001).Medline, CAS, Google Scholar
34 Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG: Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol. Cancer Res. Treat.3(5),411 (2004).Crossref, Medline, CAS, Google Scholar
35 Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR: Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology72(1),205–213 (2008).Crossref, Medline, Google Scholar
36 Qiu Y, Robinson D, Pretlow TG, Kung HJ: Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3’-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl Acad. Sci. USA95(7),3644–3649 (1998).Crossref, Medline, CAS, Google Scholar
37 Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC: Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate67(7),764–773 (2007).Crossref, Medline, CAS, Google Scholar
38 Yuan TC, Veeramani S, Lin FF et al.: Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer13(1),151–167 (2006).Crossref, Medline, CAS, Google Scholar
39 Spiotto MT, Chung TD: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate42(3),186–195 (2000).Crossref, Medline, CAS, Google Scholar
40 Deeble PD, Murphy DJ, Parsons SJ, Cox ME: Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol. Cell. Biol.21(24),8471–8482 (2001).Crossref, Medline, CAS, Google Scholar
41 Lee LF, Guan J, Qiu Y, Kung HJ: Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol. Cell. Biol.21(24),8385–8397 (2001).Crossref, Medline, CAS, Google Scholar
42 Desai SJ, Ma AH, Tepper CG, Chen HW, Kung HJ: Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Res.66(21),10449–10459 (2006).Crossref, Medline, CAS, Google Scholar
43 Jin RJ, Wang Y, Masumori N et al.: NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res.64(15),5489–5495 (2004).Crossref, Medline, CAS, Google Scholar
44 Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD: Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer71(9),2782–2790 (1993).Crossref, Medline, CAS, Google Scholar
45 Ayala G, Tuxhorn JA, Wheeler TM et al.: Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res.9(13),4792–4801 (2003).Medline, CAS, Google Scholar
46 Rowley DR: What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev.17,411–419 (1999).Crossref, CAS, Google Scholar
47 Tuxhorn JA, Ayala GE, Rowley DR: Reactive stroma in prostate cancer progression. J. Urol.166(6),2472–2483 (2001).Crossref, Medline, CAS, Google Scholar
48 Hendriksen PJ, Dits NF, Kokame K et al.: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res.66(10),5012–5020 (2006).Crossref, Medline, CAS, Google Scholar
49 Mohler JL, Gregory CW, Ford OH 3rd et al.: The androgen axis in recurrent prostate cancer. Clin. Cancer Res.10(2),440–448 (2004).Crossref, Medline, CAS, Google Scholar
50 Stanbrough M, Bubley GJ, Ross K et al.: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res.66(5),2815–2825 (2006).Crossref, Medline, CAS, Google Scholar
51 Montgomery RB, Mostaghel EA, Vessella R et al.: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res.68(11),4447–4454 (2008).Crossref, Medline, CAS, Google Scholar
52 Marks LS, Mostaghel EA, Nelson PS: Prostate tissue androgens: history and current clinical relevance. Urology72(2),247–254 (2008).Crossref, Medline, Google Scholar
53 Mostaghel EA, Nelson PS: Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract. Res. Clin. Endocrinol. Metab.22(2),243–258 (2008).Crossref, Medline, CAS, Google Scholar
54 Mostaghel EA, Page ST, Lin DW et al.: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res.67(10),5033–5041 (2007).Crossref, Medline, CAS, Google Scholar
55 Page ST, Lin DW, Mostaghel EA et al.: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J. Clin. Endocrinol. Metab.91(10),3850–3856 (2006).Crossref, Medline, CAS, Google Scholar
56 Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G: Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem.32(5),695–698 (1989).Crossref, Medline, CAS, Google Scholar
57 Mizokami A, Koh E, Fujita H et al.: The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res.64(2),765–771 (2004).Crossref, Medline, CAS, Google Scholar
58 Chun JY, Nadiminty N, Dutt S et al.: Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin. Cancer Res.15(15),4815–4822 (2009).Crossref, Medline, CAS, Google Scholar
59 Arnold JT, Gray NE, Jacobowitz K et al.: Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J. Steroid Biochem. Mol. Biol.111(3–5),240–246 (2008).Crossref, Medline, CAS, Google Scholar
60 Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T: Amplification and overexpression of androgen receptor gene in hormone- refractory prostate cancer. Cancer Res.61(9),3550–3555 (2001).Medline, CAS, Google Scholar
61 Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res.68(13),5469–5477 (2008).Crossref, Medline, CAS, Google Scholar
62 Tepper CG, Boucher DL, Ryan PE et al.: Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res.62(22),6606–6614 (2002).Medline, CAS, Google Scholar
63 Guo Z, Yang X, Sun F et al.: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res.69(6),2305–2313 (2009).Crossref, Medline, CAS, Google Scholar
64 Hu R, Dunn TA, Wei S et al.: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res.69(1),16–22 (2009).Crossref, Medline, CAS, Google Scholar
65 Jagla M, Feve M, Kessler P et al.: A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology148(9),4334–4343 (2007).Crossref, Medline, CAS, Google Scholar

Vol. 5, No. 9

Metrics

Downloaded 467 times

History

Published online 10 November 2009

Published in print November 2009

Information

Keywords

Financial & competing interests disclosure

This work was supported by NIH grants CA118887 and CA109441 (Gao), and the AUA Foundation Research Scholars Program and Astellas USA Foundation Research Scholars (Dutt). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download